NVO Stock Analysis: Buy, Sell, or Hold?
NVO - Novo-Nordisk A/S
$59.43
0.10 (0.17%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026
3d
Get Alerted When NVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called NVO this week
80% bullish • 1 bearish
80% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NVO shows positive signals but monitor for confirmation. Market pricing in 0.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NVO shows positive signals but monitor for confirmation. Market pricing in 0.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.88
Based on 0.5% avg growth
INTRINSIC VALUE TODAY
$38.42
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVO is currently trading at $59.43, which is considered slightly high relative to its 30-day fair value range of $52.81 to $61.47. The stock's valuation (Forward PE: 2.6) is in line with its historical norms (2.7). Remarkably, the market is currently pricing in an annual earnings decline of 0.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NVO is in a strong downtrend. Immediate support is located at $57.56, while resistance sits at $64.16.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVO is in a strong downtrend. Immediate support is located at $57.56, while resistance sits at $64.16.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$52.81 -
$61.47
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($59.65)
Fair Price Analysis
30-Day Fair Range
$52.81 -
$61.47
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$57.56
Resistance Level
$64.16
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
2.64
Wall Street Target
$59.65
(+0.5%)
Revenue Growth (YoY)
5.1%
Earnings Growth (YoY)
-26.5%
Profit Margin
32.9%
Valuation Discount vs History
-0.5% cheaper
PE vs Historical
2.6 vs 2.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.5%
(market-implied from PE analysis)
1-Year Target
$59.03
(-1%)
2-Year Target
$58.74
(-1%)
3-Year Target
$58.44
(-2%)
3-Yr Target (if PE normalizes)
(PE: 3→3)
$59.70
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -3.1%)
$455.19
(+667%)
Base:
(SPY PE: 2.6, Growth: -3.1%)
$53.96
(-9%)
Bear:
(PE: 2.2, Growth: -3.1%)
$45.86
(-23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 16.09 | Current EPS (TTM): $3.75
Bull Case
$132.73
(+123%)
Analyst growth 100.0%, PE expands to 17.7
Base Case
$120.66
(+103%)
Market implied 100.0%, PE stable at 16.1
Bear Case
$41.02
(-31%)
Severe decline -20.0%, PE contracts to 13.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.6 to 2.7
Stabilization Target:
$60.60
(+2.1%)
PE Expansion Potential:
+2.1%
Last updated: January 30, 2026 10:07 PM ET
Data refreshes hourly during market hours. Next update: 11:07 PM
Data refreshes hourly during market hours. Next update: 11:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced NVO Option Strategies
Professional options setups generated by AI based on today's NVO price and gamma walls.
